
Rick Haas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9495758/publications.pdf Version: 2024-02-01



DICK HAAS

#	Article	IF	CITATIONS
1	Global Patient Involvement in Sarcoma Care—A Collaborative Initiative of the Connective Tissue Oncology Society (CTOS) & Sarcoma Patients EuroNet (SPAEN). Cancers, 2022, 14, 854.	3.7	2
2	Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly. European Journal of Surgical Oncology, 2022, 48, 985-993.	1.0	3
3	The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. European Journal of Cancer, 2022, 165, 71-80.	2.8	8
4	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092â€22092 STRASS trial. Cancer, 2022, 128, 2796-2805.	4.1	14
5	Management of Synovial Sarcoma and Myxoid Liposarcoma. Surgical Oncology Clinics of North America, 2022, 31, 547-558.	1.5	2
6	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 2022, 29, 7335-7348.	1.5	13
7	Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?. Acta Oncológica, 2021, 60, 35-41.	1.8	14
8	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. JAMA Oncology, 2021, 7, e205865.	7.1	45
9	In response to: "Intraoperative radiation therapy (IORT) for soft tissue sarcoma – ESTRO IORT task force/ACROP recommendations― Radiotherapy and Oncology, 2021, 154, 170-171.	0.6	3
10	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15Âyears. Annals of Surgical Oncology, 2021, 28, 1700-1709.	1.5	38
11	Preoperative radiotherapy for retroperitoneal sarcoma – Authors' reply. Lancet Oncology, The, 2021, 22, e4.	10.7	2
12	Cellular Radiosensitivity of Soft Tissue Sarcoma. Radiation Research, 2021, 196, 23-30.	1.5	29
13	Imaging response evaluation after neoadjuvant treatment in soft tissue sarcomas: Where do we stand?. Critical Reviews in Oncology/Hematology, 2021, 160, 103309.	4.4	14
14	Treatment Strategies for Metastatic Soft Tissue Sarcomas. Cancers, 2021, 13, 1722.	3.7	5
15	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	4.1	96
16	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Annals of Surgical Oncology, 2021, 28, 7873-7888.	1.5	105
17	Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent. Annals of Surgical Oncology, 2021, 28, 7923-7936.	1.5	12
18	Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas. Radiotherapy and Oncology, 2021, 158, 33-39.	0.6	4

#	Article	IF	CITATIONS
19	Role of Radiation Therapy for Newly Diagnosed Retroperitoneal Sarcoma. Current Treatment Options in Oncology, 2021, 22, 75.	3.0	3
20	Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000–2017 Netherlands Cancer Registry Database Analysis. Sarcoma, 2021, 2021, 1-8.	1.3	5
21	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta Oncológica, 2021, 60, 1557-1564.	1.8	5
22	A moderate dose of preoperative radiotherapy may improve resectability in myxoid liposarcoma. European Journal of Surgical Oncology, 2021, 47, 2633-2639.	1.0	10
23	Descriptive analysis of MRI functional changes occurring during reduced dose radiotherapy for myxoid liposarcomas. British Journal of Radiology, 2021, 94, 20210310.	2.2	1
24	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. European Journal of Cancer, 2021, 157, 291-300.	2.8	11
25	The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting. Sarcoma, 2021, 2021, 1-6.	1.3	4
26	Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. Cancers, 2021, 13, 5780.	3.7	2
27	Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group. Journal of Clinical Medicine, 2021, 10, 5334.	2.4	2
28	Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models. Cancers, 2020, 12, 47.	3.7	12
29	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Annals of Oncology, 2020, 31, 1506-1517.	1.2	103
30	Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients. European Journal of Cancer, 2020, 141, 128-136.	2.8	13
31	Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study. Sarcoma, 2020, 2020, 1-8.	1.3	10
32	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1366-1377.	10.7	266
33	PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study. BMJ Open, 2020, 10, e039449.	1.9	7
34	Neck Lymphoma. Medical Radiology, 2020, , 441-465.	0.1	0
35	RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics. Cancers, 2020, 12, 1372.	3.7	36
36	Reply to Incidence of extrameningeal solitary fibrous tumors and Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy. Cancer. 2020, 126, 4069-4070	4.1	0

#	Article	IF	CITATIONS
37	Can we use MRI to detect clinically silent recurrent soft-tissue sarcoma?. European Radiology, 2020, 30, 4724-4733.	4.5	17
38	Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. Cancer, 2020, 126, 3002-3012.	4.1	39
39	Evolution in the management of soft tissue sarcoma: classification, surgery and use of radiotherapy. Expert Review of Anticancer Therapy, 2020, 20, 3-13.	2.4	7
40	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. European Journal of Cancer, 2020, 127, 96-107.	2.8	243
41	Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. Clinical Sarcoma Research, 2019, 9, 9.	2.3	34
42	Substantial Volume Changes and Plan Adaptations During Preoperative Radiation Therapy in Extremity Soft Tissue Sarcoma Patients. Practical Radiation Oncology, 2019, 9, 115-122.	2.1	8
43	Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands. European Journal of Cancer, 2019, 110, 98-106.	2.8	25
44	New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration. Current Opinion in Oncology, 2019, 31, 310-316.	2.4	53
45	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer, 2019, 125, 1290-1300.	4.1	71
46	Time dependent dynamics of wound complications after preoperative radiotherapy in Extremity Soft Tissue Sarcomas. European Journal of Surgical Oncology, 2019, 45, 684-690.	1.0	23
47	Considering sarcoma staging systems and their implications to personalized care. Chinese Clinical Oncology, 2019, 8, S9-S9.	1.2	0
48	Managing Extremity Soft Tissue Sarcoma Patients: Surgery Alone or in Combination with Radiotherapy? An Editorial on the Paper by Fiore et al Annals of Surgical Oncology, 2018, 25, 1461-1462.	1.5	3
49	Pre- and postoperative radiotherapy for extremity soft tissue sarcoma: Evaluation of inter-observer target volume contouring variability among French sarcoma group radiation oncologists. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 131-139.	1.4	6
50	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. Annals of Surgery, 2018, 267, 959-964.	4.2	142
51	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. Oncolmmunology, 2018, 7, e1386828.	4.6	36
52	Radiation therapy in retroperitoneal sarcoma management. Journal of Surgical Oncology, 2018, 117, 93-98.	1.7	25
53	Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Quality of Life Research, 2018, 27, 1089-1098.	3.1	32
54	Perioperative Management of Extremity Soft Tissue Sarcomas. Journal of Clinical Oncology, 2018, 36, 118-124.	1.6	33

#	Article	IF	CITATIONS
55	Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv79-iv95.	1.2	380
56	Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surgical Oncology, 2018, 27, 695-701.	1.6	33
57	ASO Author Reflections: Benefit of Adjuvant Radiotherapy for Clinical Outcome in Patients with Soft Tissue Sarcoma. Annals of Surgical Oncology, 2018, 25, 924-925.	1.5	1
58	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. Sarcoma, 2018, 2018, 1-8.	1.3	14
59	Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv68-iv78.	1.2	413
60	Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv51-iv67.	1.2	641
61	The key role of pathology, surgery and radiotherapy in the initial management of soft tissue sarcoma. Future Oncology, 2018, 14, 15-23.	2.4	6
62	Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1226-1233.	0.8	39
63	Preoperative radiotherapy in soft tissue sarcoma: from general guidelines to personalized medicine. Chinese Clinical Oncology, 2018, 7, 41-41.	1.2	11
64	ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Critical Reviews in Oncology/Hematology, 2017, 110, 94-105.	4.4	94
65	Postâ€relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transâ€Atlantic RPS Working Group. Cancer, 2017, 123, 1971-1978.	4.1	104
66	Orthovoltage X-rays for Postoperative Treatment of Resected Basal Cell Carcinoma in the Head and Neck Area. Journal of Cutaneous Medicine and Surgery, 2017, 21, 243-249.	1.2	11
67	Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers. Annals of Surgical Oncology, 2017, 24, 3279-3288.	1.5	41
68	The role of radiotherapy in the management of localized soft tissue sarcomas. Cancer Biology and Medicine, 2016, 13, 373-383.	3.0	28
69	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). Annals of Surgery, 2016, 263, 1002-1009.	4.2	392
70	External validation of a multiâ€institutional retroperitoneal sarcoma nomogram. Cancer, 2016, 122, 1417-1424.	4.1	77
71	Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma. European Journal of Surgical Oncology, 2016, 42, 891-898.	1.0	26
72	Cancer registries and randomised clinical trials in rare tumours: At the two extremes of daily clinical practice. European Journal of Cancer, 2016, 64, 113-115.	2.8	4

#	Article	IF	CITATIONS
73	Innovative radiotherapy of sarcoma: Proton beam radiation. European Journal of Cancer, 2016, 62, 112-123.	2.8	28
74	Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiotherapy and Oncology, 2016, 119, 14-21.	0.6	72
75	Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer $\hat{a} \in Soft Tissue and Bone Sarcoma Group (EORTC \hat{a} \in T) Tj$	ETQq110.7	784314 rgB1 48
76	emphasis on magnetic resonance imaging. European lournal of Cancer. 2016, 56, 37-44. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC–STBSG) recommendations for pathological examination and reporting. European Journal of Cancer, 2016, 53, 84-95.	2.8	99
77	Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Applicable to all and by all?. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 353-354.	1.8	0
78	Adjuvant Radiation for Soft Tissue Sarcomas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e634-e642.	3.8	8
79	Synchronous Hodgkin's lymphoma and schwannomas mimicking refractory Hodgkin's lymphoma. Annals of Hematology, 2015, 94, 1593-1595.	1.8	Ο
80	Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. International Journal of Radiation Oncology Biology Physics, 2015, 92, 602-612.	0.8	102
81	Retroperitoneal Sarcoma Target Volume and Organ at Risk Contour Delineation Agreement Among NRG Sarcoma Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1053-1059.	0.8	28
82	A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. Acta Oncológica, 2015, 54, 1195-1201.	1.8	53
83	Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v31-v39.	1.2	298
84	Age as an independent prognostic factor for survival of localised synovial sarcoma patients. British Journal of Cancer, 2015, 113, 1602-1606.	6.4	85
85	Present and future of radiotherapy before and after surgery for sarcoma patients. European Journal of Surgical Oncology, 2014, 40, 1595-1597.	1.0	6
86	Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. World Journal of Surgical Oncology, 2013, 11, 59.	1.9	12
87	Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT. Journal of Radiation Oncology, 2013, 2, 55-62.	0.7	30
88	Cone beam CT assisted irradiation of painful vertebral metastases without prior virtual simulation: A quick and patient friendly procedure. Radiotherapy and Oncology, 2013, 106, 375-377.	0.6	1
89	Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where?. International Journal of Radiation Oncology Biology Physics, 2012, 84, 572-580.	0.8	185
90	Oncogenesis and classification of mixedâ€ŧype liposarcoma: A radiological, histopathological and molecular biological analysis. International Journal of Cancer, 2011, 128, 778-786.	5.1	11

#	Article	IF	CITATIONS
91	Delineation of Chondroid Lipoma: An Immunohistochemical and Molecular Biological Analysis. Sarcoma, 2011, 2011, 1-5.	1.3	14
92	Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience. Annals of Surgical Oncology, 2010, 17, 686-693.	1.5	28
93	Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 27-34.	2.4	43
94	Localized Low-Dose Radiotherapy for Follicular Lymphoma: History, Clinical Results, Mechanisms of Action, and Future Outlooks. International Journal of Radiation Oncology Biology Physics, 2010, 78, 975-982.	0.8	43
95	Multifocal Myxoid Liposarcoma—Metastasis or Second Primary Tumor?. Journal of Molecular Diagnostics, 2010, 12, 238-243.	2.8	15
96	Low dose radiotherapy in indolent lymphomas, enough is enough. Hematological Oncology, 2009, 27, 71-81.	1.7	24
97	Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. Modern Pathology, 2009, 22, 223-231.	5.5	74
98	Low-Dose Involved-Field Radiotherapy as Alternative Treatment of Nodular Lymphocyte Predominance Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1199-1202.	0.8	19
99	Effectiveness of Radiotherapy in Myxoid Sarcomas Is Associated With a Dense Vascular Pattern. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1480-1487.	0.8	56
100	Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution's Experience. Annals of Surgical Oncology, 2008, 15, 1757-1764.	1.5	35
101	Neoadjuvant (Induction) Erlotinib Response in Stage IIIA Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 4205-4207.	1.6	32
102	An Unusual Case of Hemosiderotic Fibrohistiocytic Lipomatous Lesion: Correlation of MRI and Pathologic Findings. Sarcoma, 2008, 2008, 1-4.	1.3	7
103	99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nuclear Medicine Communications, 2008, 29, 39-44.	1.1	50
104	Neck Lymphoma. Medical Radiology, 2008, , 311-328.	0.1	0
105	In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood, 2007, 110, 1116-1122.	1.4	58
106	Radiotherapy preserves fingers in the management of subungual squamous cell carcinoma, obviating the need for amputation. Radiotherapy and Oncology, 2007, 85, 473-476.	0.6	9
107	Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 893-899.	6.4	27
108	Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. European Journal of Cancer, 2005, 41, 1724-1730.	2.8	53

#	Article	IF	CITATIONS
109	In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. International Journal of Radiation Oncology Biology Physics, 2004, 59, 782-787.	0.8	129
110	In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiotherapy and Oncology, 2004, 72, 333-339.	0.6	117
111	Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients. Radiotherapy and Oncology, 2003, 69, 323-328.	0.6	9
112	High Response Rates and Lasting Remissions After Low-Dose Involved Field Radiotherapy in Indolent Lymphomas. Journal of Clinical Oncology, 2003, 21, 2474-2480.	1.6	173
113	Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?. International Journal of Radiation Oncology Biology Physics, 2000, 48, 27-35.	0.8	118
114	The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. European Journal of Cancer, 1997, 33, 1055-1060.	2.8	67